Pfizer did not confirm the authenticity of the study document. Its lead authors are Sharon Alroy-Preis, head of public health for Israel’s health ministry, and Eric Haas, a ministry researcher. In addition, the study was carried out by a team of eight Pfizer researchers, including epidemiologists Farid Khan and John McLaughlin and the company’s global medical lead for covid vaccines, David Swerdlow, an infectious disease expert previously with the US Centers for Disease Control and Prevention.
The research represents the first joint report by the health ministry and Pfizer since they reached an agreement earlier this year for Israel to share vaccination data in return for a steady supply of doses.
The cooperation is part of a wider effort by Pfizer to track how its vaccine, named Comirnaty, works in large populations. The company told MIT Technology Review earlier this week that it is studying “the vaccine’s real-world effectiveness at several locations worldwide, including Israel,” and “particularly looking at real-world data from Israel to understand any potential impact of the vaccine to protect against covid-19 arising from emerging variants.” Pfizer’s vaccine, like one from Moderna, another mRNA vaccine authorized for use in the US and Europe, uses two injections of messenger RNA carrying information about the virus to train people’s immune system to recognize and combat the infection.
The new findings are broadly consistent with separate announcements in recent days from two of Israel’s large health organizations, Maccabi Healthcare Services and Clalit Health Services, which together care for 80% of Israelis.
On February 14, Ran Balicer, chief of innovation and research at Clalit, the largest Israeli HMO, said that evidence collected on 1.2 million members “shows unequivocally that Pfizer’s coronavirus vaccine is extremely effective in the real world a week after the second dose.”
Other analyses suggest that serious infections and deaths have fallen among older Israelis, who got the vaccine first, but not among those younger than 44 who have not been vaccinated.
The Israeli report describes observations made during three weeks in January and February when researchers were able to compare health records of unvaccinated people and people who had gotten their second shot more than a week before. They then compared the groups for five covid-19 outcomes: infection, symptoms, hospitalizations, critical hospitalization, and death. The unpublished study says the vaccine was around 93% effective in preventing symptomatic covid-19. Pfizer and its partner, the German biotechnology firm BioNTech, had found 95% effectiveness in their clinical trials carried out in 2020. The country-wide study was also able to show that hospitalizations and deaths dropped by similar amounts in the vaccinated group.
Because Israel tests people fairly comprehensively, the researchers were also able to estimate that the vaccine was 89.4% effective in preventing any detectable infection at all, including asymptomatic infections.
That finding, which is new, suggests that the vaccine could strongly suppress transmission of the virus between people and could help bring the outbreak to an end, a possibility Pfizer and the Israeli researchers say they are closely watching. “Israel provides a unique opportunity to observe the nation-wide impact of an increasing prevalence of immunity on Sars-Cov-2 transmission,” the authors wrote. Eric Topol, a doctor at Scripps Research in California, who reviewed the document, says that “the blocking of infections here speaks to the vaccine’s impact on asymptomatic transmission, which we’ve been unsure about.”
SpaceX has successfully landed Starship after flight for the first time
On March 3, SpaceX’s Starship pulled off a successful high-altitude flight—its third in a row. Unlike in the first two missions, the spacecraft stuck the landing. Then, as in the last two, the spacecraft blew up.
What happened: At around 5:14 p.m. US Central Time, the 10th Starship prototype (SN10) was launched from SpaceX’s test facility in Boca Chica, Texas, flying about 10 kilometers into the air before falling back down and descending safely to Earth.
About 10 minutes later, the spacecraft blew up, from what appears to have been a methane leak. Still, the actual objectives of the mission were met.
Rocket Lab could be SpaceX’s biggest rival
In the private space industry, it can seem that there’s SpaceX and then there’s everyone else. Only Blue Origin, backed by its own billionaire founder in the person of Jeff Bezos, seems able to command the same degree of attention. And Blue Origin hasn’t even gone beyond suborbital space yet.
Rocket Lab might soon have something to say about that duopoly. The company, founded in New Zealand and headquartered in Long Beach, California, is second only to SpaceX when it comes to launch frequency—the two are ostensibly the only American companies that regularly go to orbit. Its small flagship Electron rocket has flown 18 times in just under four years and delivered almost 100 satellites into space, with only two failed launches.
On March 1, the company made its ambitions even clearer when it unveiled plans for a new rocket called Neutron. At 40 meters tall and able to carry 20 times the weight that Electron can, Neutron is being touted by Rocket Lab as its entry into markets for large satellite and mega-constellation launches, as well as future robotics missions to the moon and Mars. Even more tantalizing, Rocket Lab says Neutron will be designed for human spaceflight as well. The company calls it a “direct alternative” to the SpaceX Falcon 9 rocket.
“Rocket Lab is one of the success stories among the small launch companies,” says Roger Handberg, a space policy expert at the University of Central Florida. “They are edging into the territory of the larger, more established launch companies now—especially SpaceX.”
That ambition was helped by another bit of news announced on March 1: Rocket Lab’s merger with Vector Acquisition Corporation. Joining forces with a special-purpose acquisition company, a type of company that ostensibly enables another business to go public without an IPO, will allow Rocket Lab to benefit from a massive influx of money that gives it a new valuation of $4.1 billion. Much of that money is going toward development and testing of Neutron, which the company wants to start flying in 2024.
It’s a bit of an about-face for Rocket Lab. CEO Peter Beck had previously been lukewarm about the idea of building a larger rocket that could launch bigger payloads and potentially offer launches for multiple customers at once.
But the satellite market has embraced ride-share missions into orbit, especially given the rise of satellite mega-constellations, which will probably make up most satellites launched into orbit over the next decade. Neutron is capable of taking 8,000 kilograms to low Earth orbit, which means it could deliver potentially dozens of payloads to orbit at once. As a lighthearted mea culpa, the introductory video for Neutron showed Beck eating his own hat.
Recovering from the SolarWinds hack could take 18 months
SolarWinds Orion, the network management product that was targeted, is used in tens of thousands of corporations and government agencies. Over 17,000 organizations downloaded the infected back door. The hackers were extraordinarily stealthy and specific in targeting, which is why it took so long to catch them—and why it’s taking so long to understand their full impact.
The difficulty of uncovering the extent of the damage was summarized by Brad Smith, the president of Microsoft, in a congressional hearing last week.
“Who knows the entirety of what happened here?” he said. “Right now, the attacker is the only one who knows the entirety of what they did.”
Kevin Mandia, CEO of the security company FireEye, which raised the first alerts about the attack, told Congress that the hackers prioritized stealth above all else.
“Disruption would have been easier than what they did,” he said. “They had focused, disciplined data theft. It’s easier to just delete everything in blunt-force trauma and see what happens. They actually did more work than what it would have taken to go destructive.”
“This has a silver lining”
CISA first heard about a problem when FireEye discovered that it had been hacked and notified the agency. The company regularly works closely with the US government, and although it wasn’t legally obligated to tell anyone about the hack, it quickly shared news of the compromise with sensitive corporate networks.
It was Microsoft that told the US government federal networks had been compromised. The company shared that information with Wales on December 11, he said in an interview. Microsoft observed the hackers breaking into the Microsoft 365 cloud that is used by many government agencies. A day later, FireEye informed CISA of the back door in SolarWinds, a little-known but extremely widespread and powerful tool.
This signaled that the scale of the hack could be enormous. CISA’s investigators ended up working straight through the holidays to help agencies hunt for the hackers in their networks.
These efforts were made even more complicated because Wales had only just taken over at the agency: days earlier, former director Chris Krebs had been fired by Donald Trump for repeatedly debunking White House disinformation about a stolen election.